drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous gene-modified T-cell therapy engineered via Sleeping Beauty to express a ROR1-targeted CAR, membrane-bound IL-15, an EGFRt/HER1t safety switch, and intrinsic PD-1 downregulation to recognize and kill ROR1+ tumor cells with enhanced persistence and resistance to PD-1/PD-L1 suppression.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a ROR1-targeted chimeric antigen receptor to recognize and kill ROR1-positive tumor cells; membrane-bound IL-15 enhances T-cell survival and expansion; intrinsic PD-1 downregulation resists PD-1/PD-L1–mediated inhibition; an EGFRt/HER1t safety switch allows conditional ablation of the cells.
drug_name
PRGN-3007 UltraCAR-T
nct_id_drug_ref
NCT05694364